Vimarsana
Biggest News Aggregation in the World

Page 38 - Nasdaq First News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq First. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq First Today - Breaking & Trending Today

EWPG Holding AB (publ): Eco Wave Power Announces Submission of Formal Application for Delisting from Nasdaq First North Growth Market in Stockholm as Part of U.S. Focus - Vimarsana News

EWPG Holding AB (publ): Eco Wave Power Announces Submission of Formal Application for Delisting from Nasdaq First North Growth Market in Stockholm as Part of U.S. Focus

ADSs Will Continue to Trade on the Nasdaq Capital Market in the U.S. STOCKHOLM, May 26, 2022 /PRNewswire/ -- Eco Wave Power Global AB (publ) (NASDAQ: WAVE) (NASDAQ First North: ECOWVE)

Nasdaq Stockholm AB: Delisting of equity rights in Mavshack AB from Nasdaq First North Growth Market (247/22) - Vimarsana News

Nasdaq Stockholm AB: Delisting of equity rights in Mavshack AB from Nasdaq First North Growth Market (247/22)

Mavshack AB has applied for its equity rights to be delisted from Nasdaq First North Growth Market. Nasdaq Stockholm AB has approved the application and decided to delist the equity rights in Mavshack

Faron Announces US Food and Drug Administration and Finnish Medicines Agency Approval to Initiate Phase I/II Bexmarilimab Combination Study in Hematologic Malignancies - Vimarsana News

Faron Announces US Food and Drug Administration and Finnish Medicines Agency Approval to Initiate Phase I/II Bexmarilimab Combination Study in Hematologic Malignancies

Faron Pharmaceuticals Ltd. ("Faron" or "Company") Faron Announces US Food and Drug Administration and Finnish Medicines Agency Approval to Initiate Phase I/II...

Investegate |Faron Pharma. Oy Announcements | Faron Pharma. Oy: FDA and FIMEA approve BEXMAB study to begin - Vimarsana News

Investegate |Faron Pharma. Oy Announcements | Faron Pharma. Oy: FDA and FIMEA approve BEXMAB study to begin

Investegate announcements from Faron Pharma. Oy, FDA and FIMEA approve BEXMAB study to begin

Investegate |Faron Pharma. Oy Announcements | Faron Pharma. Oy: Ex Vivo Data Presented at EHA2022 Congress - Vimarsana News

Investegate |Faron Pharma. Oy Announcements | Faron Pharma. Oy: Ex Vivo Data Presented at EHA2022 Congress

Investegate announcements from Faron Pharma. Oy, Ex Vivo Data Presented at EHA2022 Congress